) remained unchanged after the release of third quarter 2013
earnings but were up 2.7% % in the next trading session. Overall,
shares gained 2.7% since the company reported third quarter
ArQule reported a loss of 10 cents per share in the third
quarter of 2013, narrower than the Zacks Consensus Estimate of a
loss of 13 cents per share. The company had reported a loss of a
penny in the year-ago quarter.
Revenues plummeted 67.6% to $3.5 million in the third quarter
of 2013, but surpassed the Zacks Consensus Estimate of $3
Quarter in Detail
The decline in ArQule's quarterly revenues was primarily due
to the reduction of $4.5 million of revenues from the company's
research collaboration with Daiichi Sankyo that ended in Nov 2012
and $2.3 million from the tivantinib program with the latter. In
addition, revenues were also negatively impacted by $0.6 million
from the Daiichi Sankyo ARQ 092 agreement that ended in Jun
Research and development expenses were $8.1 million, down
26.9% from the year-ago quarter mainly due to lower outsourced
clinical and product development costs related to tivantinib and
other pipeline programs along with lower labor related costs.
We remind investors that ArQule announced a workforce
reduction of approximately 25 positions in order to accumulate
cash and sustain its business into 2016, independently fund its
clinical trials and effectively deploy core discovery
capabilities concurrent with the second quarter results. The
restructuring activities are expected to result in annual cost
savings of approximately $3.5- $4.0 million starting in 2014.
General and administrative expenses declined 8.1% to $3.1
2013 Outlook Updated
ArQule now expects revenues between $13 million and $16
million in 2013, up from the earlier estimate of $12 - $15
million. The pre-earnings Zacks Consensus Estimate of $15 million
was well within the new guidance. ArQule anticipates net loss per
share between 42 cents and 46 cents compared to the previous
projection of 45 cents to 50 cents in 2013. The Zacks
Consensus Estimate for 2013 hints at a loss of 46 cents.
ArQule will continue to focus on developing its oncology
candidate, tivantinib (ARQ 197). As per the recommendation
from the the Data Monitoring Committee, the company submitted an
amended protocol related to a lower dose of 120 milligrams (mg)
twice daily in the phase III METIV-HCC trial of tivantinib as
single agent therapy in patients suffering from hepatocellular
ArQule presented encouraging data from a randomized,
double-blind, placebo-controlled phase III trial, MARQUEE, on
tivantinib at the European Cancer Congress in Sep 2013. The data
showed the clinical benefits of treatment with the combination of
) Tarceva (erlotinib) in patients suffering from non-squamous,
non-small cell lung cancer (NSCLC) whose tumors expressed high
levels of MET protein.
ArQule currently carries a Zacks Rank #3 (Hold). Right now,
) look attractive. While Jazz Pharma carries a Zacks Rank #1
(Strong Buy), Salix Pharma carries a Zacks Rank #2 (Buy).
ARQULE INC (ARQL): Free Stock Analysis Report
JAZZ PHARMACEUT (JAZZ): Free Stock Analysis
ROCHE HLDG LTD (RHHBY): Get Free Report
SALIX PHARM-LTD (SLXP): Free Stock Analysis
To read this article on Zacks.com click here.